Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant-based quadruple versus triple antiemetic prophylaxis for multiday cisplatin chemotherapy
ChiCTR2100046303Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fosaprepitant, olanzapine, palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Ordos Central Hospital. Primary endpoint: overall phase complete response. Started Jun 2021; status: recruiting.
02
Drugs
fosaprepitantolanzapinepalonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2100046303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046303.